A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes

NCT04591626 on ClinicalTrials.gov · last registry update 2023-05-24

Finished 28 April 2022, after enrolling 291 people. Primary outcome, as filed: Change From Baseline in Hemoglobin A1c (HbA1c). dulaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: dulaglutide
Trulicity
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 291
Started: 2020-12-07
Primary completion: 2022-04-28 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline in Hemoglobin A1c (HbA1c)

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.